GHRH Analogues

About this category

Growth hormone-releasing hormone (GHRH) analogues are synthetic peptides modelled on the endogenous 44-amino-acid hypothalamic releasing hormone, or on its shorter biologically active fragment. Compounds in this class are structural variants: sequences are truncated, substituted at positions prone to enzymatic cleavage, or modified at the terminus to alter stability in solution. Tesamorelin and the CJC-1295 series are the analogues most often encountered in the published literature.

Mechanistically, this family is studied for its interaction with the GHRH receptor, a class B G-protein-coupled receptor. Laboratory investigation typically centres on receptor binding affinity, downstream cyclic AMP signalling in transfected cell lines, and the comparative enzymatic stability of modified sequences against the unmodified parent peptide. Because the substitutions in this class are largely aimed at resisting dipeptidyl peptidase cleavage, degradation kinetics is a recurring theme in the preclinical record.

Common in vitro applications include receptor characterisation assays, structure-activity relationship work across sequence variants, analytical method development, and formulation and stability studies on the lyophilised material. Reconstitution behaviour and cold-chain handling are relevant variables in each of these.

Every vial in this category is supplied lyophilised and carries a batch number matching a certificate of analysis published in our COA library. For referenced background on the compounds we supply, see the research hub, where each article carries its own citation list.

These materials are supplied strictly for in-vitro laboratory research. They are not medicines, are not licensed for human or veterinary use, and no guidance on use in humans or animals is offered or implied.